Assistant Professor of Biomedical Informatics
Harvard Medical School
Dr. Farhat is an Assistant Professor of of
Biomedical Informatics atHarvard Medical School and a a practicing physician at
the Massachusetts General Hospital Division of Pulmonary and Critical Care
Medicine.
Dr. Farhat's research focuses on the development and application of methods for associating genotype and phenotype in infectious disease pathogens, with a strong emphasis on translation to better diagnostics and surveillance in resource-poor settings. Farhat's work has focused on bacterial and viral pathoges and spans the spectrum from computational analysis to field studies. She is PI and Co-Investigator on several large projects funded by NIH including the NIAID and the BD2K initiative.
Maha Farhat holds an MD from the McGill University Faculty of Medicine and a MSc in biostatistics from the Harvard Chan School of Public Health.
Assistant Professor of Biomedical Informatics
Harvard Medical School
Dr. Farhat is an Assistant Professor of of
Biomedical Informatics atHarvard Medical School and a a practicing physician at
the Massachusetts General Hospital Division of Pulmonary and Critical Care
Medicine.
Dr. Farhat's research focuses on the development and application of methods for associating genotype and phenotype in infectious disease pathogens, with a strong emphasis on translation to better diagnostics and surveillance in resource-poor settings. Farhat's work has focused on bacterial and viral pathoges and spans the spectrum from computational analysis to field studies. She is PI and Co-Investigator on several large projects funded by NIH including the NIAID and the BD2K initiative.
Maha Farhat holds an MD from the McGill University Faculty of Medicine and a MSc in biostatistics from the Harvard Chan School of Public Health.
Journal article
CONCLUSIONS: Baseline within-host pathogen genetic diversity is an independent predictor of unfavorable TB treatment outcomes. As sequencing becomes increasingly integrated into routine diagnostics, quantifying unfixed variants is an accessible approach that promises to risk-stratify patients and guide the duration of individualized regimens.
Journal article
The rapid emergence of resistance to novel tuberculosis drugs, such as bedaquiline, is a key threat to the long-term effectiveness of novel regimens. Given that the introduction of these agents has enabled the introduction of an all-oral regimen for rifampicin-resistant and multidrug-resistant tuberculosis, the rise of resistance underscores the urgent need to safeguard their efficacy and responsible use. A major barrier is the delay in developing reliable tools to detect resistance to novel...